Verastem Acquires Rights to Cancer Stem Cell Inhibitor VS-4718

[Business Wire] – Verastem, Inc. , focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that it has acquired the license to VS-4718 held originally by Poniard Pharmaceuticals. more

View todays social media effects on VSTM

View the latest stocks trending across Twitter. Click to view dashboard

See who Verastem is hiring next, click here to view